CLONAL NATURE OF THE IMMUNE RESPONSE NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


CLONAL NATURE OF THE IMMUNE RESPONSE

Immunol Ser; 43:127-43 1989. Unique Identifier : AIDSLINE ICDB/90657860
Scott DW; Univ. of Rochester Cancer Center and Sch. of Medicine and; Dentistry, Rochester, NY


Abstract: Vertebrates have evolved an immune system consisting of both specific and nonspecific defense barriers, which interface with one another to protect the integrity of the organism in a hostile environment. Once potentially pathogenic agents pass through the first lines of defense (skin and mucosal tissues), they interact with both phagocytic cells and lymphocytes, which cooperate to produce humoral or cellular immunity. The biology of clonal selection, clonal growth of T cells, clonal growth of B cells, and disease relevance (AIDS) are discussed, including: Burnet-Jerne clonal selection theory; evidence for one-cell:one-specificity; development of the repertoire; recirculation and recruitment; physiologic changes in lymphoid tissues; antigen recognition by T cells; interleukins and T-cell growth; the anti-mu model; antigen and B-cell subsets; B-cell lymphomas and autocrine growth; and differentiation of B cells and isotype switching. The immune system develops its capacity to respond to different antigens at different times in life, culminating in a diverse and immunocompetent repertoire before the individual is sexually mature. Specific lymphocytes circulate until they encounter an antigen for which they have an affinity. They then remove themselves from the circulation and begin the process known as the specific immune response. Although the exact biochemical mechanisms for the receipt of immunologic signals leading to gene transcription and RNA splicing are unclear, the system eventually condenses into three interacting entities: a T cell, a B cell, and an antigen. The affinity of these cells for antigen through different kinds of molecular receptors and for each other, through major histocompatibility complex interaction and a variety of lymphokines, promotes the clonal expansion of individual cells and the manifestation of an immune response. This ultimately leads to amplification and the inflammation mechanism culminating in the removal of pathogenic organisms. In AIDS, the CD4 helper T cells harbor the human immunodeficiency virus (HIV), putting the system at enormous risk for destruction from within. The CD4 molecule may be the anchor to which HIV attaches itself. (40 Refs)
Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Animal *Antibody Formation Antigen-Presenting Cells/IMMUNOLOGY Antigenic Variation Antigens/IMMUNOLOGY B-Lymphocytes/*IMMUNOLOGY Clone Cells/IMMUNOLOGY Human *Immunity, Cellular Interleukin-4/IMMUNOLOGY Lymphoid Tissue/IMMUNOLOGY/PHYSIOLOGY Lymphokines/IMMUNOLOGY Lymphoma/IMMUNOLOGY Major Histocompatibility Complex T-Lymphocytes/*IMMUNOLOGY Tumor Cells, Cultured/IMMUNOLOGY JOURNAL ARTICLE REVIEW REVIEW, TUTORIALKWDacquiredimmunodeficiencysyndrome/immunologyanimalKWDantibodyformationantigen-presentingcells/immunologyantigenicvariationantigens/immunologyb-lymphocytes/KWDimmunologyclonecells/immunologyhumanKWDimmunity,cellularinterleukin-4/immunologylymphoidtissue/immunology/physiologylymphokines/immunologylymphoma/immunologymajorhistocompatibilitycomplext-lymphocytes/KWDimmunologytumorcells,cultured/immunologyjournalarticlereviewreview,tutorial
900330
M9030725

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .